A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II-study design and rationale

American Heart Journal

Volumn 155, Issue 4, 2008, Pages 600-608

  Mehta, Rajendra H ^a   Alexander, John H ^a   Emery, Robert ^b   Ellis, Stephen J ^a   Hasselblad, Vic ^a   Khalil, Ahmad ^c   Carrier, Michel ^d   Harrington, Robert A ^a   Tardif, Jean Claude ^d  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b Minnesota Heart and Vascular Center   (United States)

^c Medicure International Inc   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PYRIDOXAL 5 PHOSPHATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE NECROSIS; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; STATISTICAL ANALYSIS; SURVIVAL TIME;

CARDIOVASCULAR DISEASES; CORONARY ARTERY BYPASS; CORONARY DISEASE; DOUBLE-BLIND METHOD; HUMANS; MYOCARDIAL INFARCTION; POSTOPERATIVE COMPLICATIONS; PYRIDOXAL PHOSPHATE; RESEARCH DESIGN;

EID: 40849145387     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.01.002     Document Type: Article

References (25)

1. Eagle K.A., Guyton R.A., Davidoff R., et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 110 (2004) e340-e437
2. American Heart Association. Heart disease and stroke statistics-2007 update (2007), American Heart Association, Dallas (Tex). http://www.americanheart.org/presenter.jhtml?identifier=3000090 (accessed August 20, 2007)
3. The PREVENT Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery-PREVENT IV: a randomized controlled trial. JAMA 294 (2005) 2446-2454
4. Edwards F.H., Clark R.E., and Schwartz M. Coronary artery bypass grafting: the Society of Thoracic Surgeons National Database experience. Ann Thorac Surg 57 (1994) 12-19
5. Desai N.D., Cohen E.A., Naylor C.D., et al., for the Radial Artery Patency investigators. N Engl J Med 351 (2004) 2302-2309
6. Theroux P., Chaitman B.R., Danchin N., et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations: main results of the GUARDIAN trial. Circulation 102 (2000) 3032-3038
7. Plume S.K., O'Connor G.T., and Omstead E.M. Changes in patients undergoing coronary artery bypass grafting:1987-1990: update in 2000. Ann Thorac Surg 72 (2001) 314-315
8. Ferguson T.B., Hamill P.G., Peterson E.D., et al. A decade of change-risk profiles and outcomes for isolated coronary artery bypass grafting procedures, 1990-1999: a report from the STS National Database Committee and the Duke Clinical Research Institute. Ann Thorac Surg 73 (2002) 480-490
9. Klatte K., Chaitman B.R., Theroux P., et al. Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release: results from the GUARDIAN trial. J Am Coll Cardiol 38 (2001) 1070-1077
10. O'Connor G.T., Birkmeyer J.D., Dacey L.J., et al. Results of a regional study of modes of death associated with coronary artery bypass grafting. Ann Thoracic Surg 66 (1998) 1323-1328
11. Van Dijk D., Keizer A.M., Diephuis J.C., et al. Neurocognitive dysfunction after coronary artery bypass surgery: a systematic review. J Thorac Cardiovasc Surg 120 (2000) 632-639
12. Wang X., Dakshinamurti K., Musat S., et al. Pyridoxal 5′-phosphate is an ATP-receptor antagonist in freshly isolated rat cardiomyocytes. J Mol Cell Cardiol 31 (1999) 1063-1072
13. Kandzari D.E., Dery J.P., Armstrong P.W., et al. MC-1 (pyridoxal 5′-phosphate): novel therapeutic applications to reduce ischaemic injury. Expert Opin Investig Drugs 14 (2005) 1435-1442
14. Wang C.X., Yang T., Noor R., et al. Role of MC-1 alone and in combination with tissue plasminogen activator in focal ischemic brain injury in rats. J Neurosurg 103 (2005) 165-169
15. Kandzari D.E., Labinaz M., Cantor W.J., et al. Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial). Am J Cardiol 92 (2003) 660-664
16. Burnstock G. Vascular control of purines with emphasis on the coronary system. Eur Heart J 10 Suppl F (1989) 15-21
17. Tardif J.C., Carrier M., Kandzari D.E., et al. Effects of pyridoxal-5′-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study. J Thorac Cardiovasc Surg 133 (2007) 1604-1611
18. Shernan S.K., Fitch J.C.K., Nussmeier N.A., et al. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg 77 (2004) 942-950
19. Verrier E.D., Sherman S.K., Taylor K.M., et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass. JAMA 291 (2004) 2319-2327
20. Smith P.K., Carrier M., Chen J.C., et al. Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time. Ann Thorac Surg 82 (2006) 781-789
21. Carrier M., Menasche P., Levy J.H., et al. Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery. Ann Thorac Surg 131 (2006) 352-356
22. Brener S.J., Lytle B.W., Schneider J.P., et al. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol 40 (2002) 1961-1967
23. Costa M.A., Carere R.G., Lichtenstein S.V., et al. Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the Arterial Revascularization Therapies Study (ARTS). Circulation 104 (2001) 2689-2693
24. Steuer J., Hörte L.G., Lindahl B., et al. Impact of perioperative myocardial injury on early and long-term outcome after coronary artery bypass grafting. Eur Heart J 23 (2002) 1219-1227
25. Haverich A., Shernan S.K., Levy J.H., et al. Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. Ann Thorac Surg 82 (2006) 486-492